BTMD
biote Corp.2.6700
+0.0500+1.91%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
127.76MP/E (TTM)
3.38Basic EPS (TTM)
0.79Dividend Yield
0%Recent Filings
8-K
Biote Q3 revenue dips 6.7%
Biote Corp. reported Q3 2025 revenue of $48.0 million, down 6.7% year-over-year, with procedure revenue dropping 10.4% amid commercial team restructuring, yet gross margin rose to 71.8% from manufacturing efficiencies. Net income fell to $9.2 million from $12.7 million, while Adjusted EBITDA declined 20.5% to $12.9 million. The company repurchased one million shares and amended settlements to repurchase founder shares for $12.5 million and $18.5 million, saving costs. Biote reiterates 2025 guidance of revenue above $190 million and Adjusted EBITDA above $50 million. Commercial shifts challenge short-term growth.
10-Q
Q2 FY2025 results
Biote Corp. posted steady revenue of $48.9M for Q2 FY2025 ended June 30, 2025, down 0.6% y/y but up 3.3% q/q (derived), as dietary supplement sales climbed 30.5% y/y to $10.7M via Amazon e-commerce while pellet procedures dipped 8.4% y/y from clinic attrition. Gross margin expanded to 71.6% from 68.8% y/y, driving operating income up 72.7% y/y to $10.8M on Asteria Health integration savings; yet net income of $3.9M trailed operating profit due to $1.8M earnout fair-value loss and $2.9M interest. Diluted EPS held at $0.10 on 31.7M shares, reconciling cleanly without anti-dilution flags. Cash dipped to $19.6M after $25.1M share repurchase liability payments, but $50M revolver stands fully available against $104.7M term debt maturing 2027 at 7.18%; free cash flow not disclosed in the 10-Q. Restructuring trimmed 7.2% of staff for efficiency. Ongoing NIL litigation with founders poses reputational risks.
8-K
Biote Q2 earnings mixed
Biote Corp. reported Q2 2025 revenue of $48.9 million, down slightly from $49.2 million last year, but swung to net income of $3.9 million from a $10.4 million loss, fueled by 71.6% gross margins and 19.1% Adjusted EBITDA growth to $15.2 million. The company launched a reorganization in May to boost clinic growth and sales productivity, yet lowered full-year guidance to revenue above $190 million and Adjusted EBITDA above $50 million amid commercial shifts. Restructuring costs hit $0.6 million.
8-K
Biote appoints finance expert to board
Biote Corp. appointed Richard R. Barrera, founder of Roystone Capital and a top institutional shareholder, to its Board of Directors on June 5, 2025, filling the vacancy left by Steven J. Heyer's resignation. Barrera, deemed independent, joins the Nominating and Corporate Governance Committee, bringing over 20 years of investment expertise to guide growth strategies. He receives a $50,000 annual retainer and initial equity award valued at $337,500, vesting over three years. This move aligns investor interests with board oversight.
8-K
Board member resigns immediately
biote Corp. announced the immediate resignation of board member Steven J. Heyer on June 2, 2025, with no disagreements over operations, policies, or practices cited. The board has yet to name a replacement, leaving the seat vacant for now. No further details on succession emerged. This shift arrives amid the company's emerging growth status.
AIBT
Aibotics Inc.
0.00+0.00
AIRS
AirSculpt Technologies, Inc.
2.57-0.06
BDMD
Baird Medical Investment Holdin
1.37+0.02
BICX
BioCorRx Inc.
0.34-0.04
BSEM
BioStem Technologies, Inc.
3.84-0.11
BTCY
Biotricity Inc.
0.38+0.04
CPMD
Cannapharmarx Inc.
0.00-0.00
IBO
Impact BioMedical, Inc.
0.44-0.02
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
NUTX
Nutex Health Inc.
171.72-4.06